A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Completed
UCB Pharma
Phase 3
2005-06-01
A 24 week study in which patients are given study medication and assessed for signs and
symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage
during the study.
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
Withdrawn
UCB Pharma
Phase 3
2007-11-01
The primary aim of this study is allow the patients suffering from Crohn's disease , who both
completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from
the treatment, to receive treatment with certolizumab pegol until the drug is available for
the Crohn's disease indication in Greece.
Dosing Flexibility Study in Patients With Rheumatoid Arthritis
Completed
UCB Pharma
Phase 4
2007-12-01
During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and
4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and
16. At Wk 18 patients will be grouped as responders or non-responders based on results of the
ACR20 at Week 16.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
